Apollo Hospitals Enterprise Ltd posted a robust performance in Q3 FY25, with net profit soaring 49% year-on-year to ₹379.4 crore, outpacing market expectations. The strong bottom-line growth was driven by higher revenues, improved operational efficiency, and a steady rise in patient volumes.

The company’s revenue for the quarter stood at ₹5,526.9 crore, marking a 13.9% increase from ₹4,850.6 crore in the same period last year.

While revenue growth was in line with estimates, EBITDA rose 24% YoY to ₹761.4 crore, slightly missing the CNBC-TV18 poll estimate of ₹771.6 crore.

The operating margin improved to 13.8% from 13% in Q3 FY24, but remained slightly below street estimates of 14%.

The hospital chain continues to benefit from strong demand for healthcare services, an expanding presence in tier-2 and tier-3 cities, and a growing contribution from its digital health and pharmacy businesses.

Also read: Grasim Industries misses Q3 estimates, swings to loss of ₹169 crore

Analysts have highlighted that Apollo’s strategic focus on integrating technology into healthcare services, along with expanding hospital capacity, is helping sustain revenue growth and profitability.

The company’s board has also declared an interim dividend of ₹9 per share (180% of the face value of ₹5 per share) for the financial year ending March 31, 2025, rewarding shareholders amid the strong financial performance.

Apollo Hospitals’ stock closed at ₹6,766 per share on the BSE, down 0.3% ahead of the results announcement.